Answers are grounded in this paper and cite their sources.
Anti-interleukin (IL)5/5Rα monoclonal antibody (mAb) therapies deplete blood eosinophils and reduce the annualised asthma attack rate by over 50%. The clinical benefits of oral corticosteroids (OCS) to treat breakthrough attacks are uncertain. Fractional exhaled nitric oxide (FENO) has the potential to discriminate between ongoing type-2 airway inflammation or infection in breakthrough attacks on mepolizumab.
No takes yet. Share an insight, caveat, or question.
Howell et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: